deltatrials
Completed PHASE2 NCT02289209

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Sponsor: Dan Zandberg

Conditions Carcinoma, Squamous Cell of Head and Neck Recurrent Head and Neck Cancer
Interventions MK-3475 Reirradiation
Updated 18 times since 2017 Last updated: Feb 13, 2025 Started: Mar 9, 2016 Primary completion: Aug 31, 2023 Completion: Aug 31, 2024

Listed as NCT02289209, this PHASE2 trial focuses on Carcinoma, Squamous Cell of Head and Neck and Recurrent Head and Neck Cancer and remains completed. Sponsored by Dan Zandberg, it has been updated 18 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

18 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 13 earlier versions

  1. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jun 2022 — May 2023 [monthly]

    Recruiting PHASE2

  3. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  4. Mar 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Jun 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. May 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE2

  10. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Apr 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dan Zandberg
  • Merck Sharp & Dohme LLC
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States
  • • Philadelphia, United States
  • • Pittsburgh, United States